FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387440328> ?p ?o ?g. }

• W4387440328 endingPage "10" @default.
• W4387440328 startingPage "1" @default.
• W4387440328 abstract "ABSTRACTIntroduction Difficult-to-treat resistance (DTR) is a newly proposed resistance phenotype characterized by resistance to all first-line drugs. The emergence of DTR as a new resistance phenotype has significant implications for clinical practice. This new concept has the potential to be widely used instead of traditional phenotypes.Areas covered This study carried out a detailed analysis about the definition, application, and evolution of various resistance phenotypes. We collected all the research articles on Gram-negative bacteria with difficult-to-treat resistance (GNB-DTR), analyzed the DTR in each region and each bacterial species. The advantages and doubts of DTR, the dilemma of GNB-DTR infections and the potential therapeutic strategies are summarized in the review.Expert opinion Available studies show that the prevalence of GNB-DTR is not optimistic. Unlike traditional resistance phenotypes, DTR is more closely aligned with the clinical treatment perspective and can help with the prompt selection of an appropriate treatment plan. Currently, potential treatment options for GNB-DTR include a number of second-line drugs and novel antibiotics. However, the definition of first-line drugs is inherently dynamic. Therefore, the DTR concept based on first-line drugs needs to be continuously updated and refined, considering the emergence of new antibiotics, resistance characteristics, and pathogen prevalence in different regions.KEYWORDS: Difficult-to-treat resistanceGram-negative bacteriaGNB-DTRprevalencepotential treatment options Article highlights This study carried out a detailed analysis about the definition, application, and evolution of various resistance phenotypes (PDR, XDR, MDR, CR, ECR, FQR, DTR).Available studies show that the prevalence of GNB-DTR is not optimistic, particularly in Pseudomonas aeruginosa and Acinetobacter baumannii, with an average proportion of DTR reaching 14.95% and 56.2%, respectively.Currently, potential treatment options for GNB-DTR include a number of second-line drugs and novel antibiotics. Colistin/polymyxin B, aminoglycosides and tigecycline have good in vitro activity against GNB-DTR, as their clinical use is limited by their adverse reactions. Cefiderocol, novel β-lactam and β-lactam-β-lactamase inhibitor combinations have been used clinically to successfully cure infections caused by GNB-DTR.Several studies have highlighted the correlation between infections caused by antibiotic-resistant bacteria and negative patient outcomes, such as prolonged hospital stays, increased incidence rates, and higher mortality rates. The treatment dilemma of GNB-DTR infection is primarily due to the high level of resistance to first-line drugs, the potential for adverse reactions with second-line drugs, and the limited availability of new antibiotics.The advantages of DTR are summarized below. Firstly, compared to traditional resistance phenotypes, such as PDR and XDR, the DTR phenotype is more straightforward and clear-cut. Secondly, infections caused by DTR have a higher mortality rate compared to other single-variety resistance phenotypes. Thirdly, it helps clinicians quickly adopt appropriate empirical treatment regimens and prevent adverse consequences.Definition of DTR may become outdated with the introduction of new antibiotics, particularly when it comes to evaluating first-line treatments. First-line drugs for different types of bacteria are constantly changing, which also affects the specific antibiotics involved in DTR.Declaration of financial/other relationshipsThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Author contributionsJJZ conceived the original idea, formulated the study conception, performed the statistical analysis and drafted first version of the manuscript. BBL searched the literature and sort it out. HZ engaged in extracting the relevant data. LYC performed the judgment of controversy in the process of data extraction. YC contributed to the original idea conception, data interpretation and manuscript revision. All authors reviewed and approved the final manuscript and agreed to be accountable for all aspects of the work.Additional informationFundingThis work was supported by the National Natural Science Foundations of China [82073894], Cultivation Project of PLA General Hospital for Distinguished Young Scientists [2020-JQPY-004] and New Medicine Clinical Research Fund [4246Z512]." @default.
• W4387440328 created "2023-10-10" @default.
• W4387440328 creator A5024120345 @default.
• W4387440328 creator A5029906760 @default.
• W4387440328 creator A5030053975 @default.
• W4387440328 creator A5049194896 @default.
• W4387440328 creator A5073378602 @default.
• W4387440328 date "2023-10-09" @default.
• W4387440328 modified "2023-10-10" @default.
• W4387440328 title "An overview of gram-negative bacteria with difficult-to-treat resistance: definition, prevalence, and treatment options" @default.
• W4387440328 cites W1992870667 @default.
• W4387440328 cites W2094812731 @default.
• W4387440328 cites W2103077615 @default.
• W4387440328 cites W2122011172 @default.
• W4387440328 cites W2123677996 @default.
• W4387440328 cites W2136060795 @default.
• W4387440328 cites W2142343447 @default.
• W4387440328 cites W2169800903 @default.
• W4387440328 cites W2558537198 @default.
• W4387440328 cites W2616409827 @default.
• W4387440328 cites W2762372373 @default.
• W4387440328 cites W2786314763 @default.
• W4387440328 cites W2799608779 @default.
• W4387440328 cites W2806428847 @default.
• W4387440328 cites W2883234304 @default.
• W4387440328 cites W2899841051 @default.
• W4387440328 cites W2900555106 @default.
• W4387440328 cites W2918952258 @default.
• W4387440328 cites W2920984710 @default.
• W4387440328 cites W2921001759 @default.
• W4387440328 cites W2922530346 @default.
• W4387440328 cites W2924739878 @default.
• W4387440328 cites W2950651849 @default.
• W4387440328 cites W2952699331 @default.
• W4387440328 cites W2969382641 @default.
• W4387440328 cites W2970603088 @default.
• W4387440328 cites W2989637146 @default.
• W4387440328 cites W2991009044 @default.
• W4387440328 cites W3003554341 @default.
• W4387440328 cites W3006102377 @default.
• W4387440328 cites W3014261949 @default.
• W4387440328 cites W3024693033 @default.
• W4387440328 cites W3033805500 @default.
• W4387440328 cites W3085250904 @default.
• W4387440328 cites W3088003513 @default.
• W4387440328 cites W3091573243 @default.
• W4387440328 cites W3102266008 @default.
• W4387440328 cites W3106009346 @default.
• W4387440328 cites W3159014701 @default.
• W4387440328 cites W3163468014 @default.
• W4387440328 cites W3170922870 @default.
• W4387440328 cites W3175187279 @default.
• W4387440328 cites W3187177963 @default.
• W4387440328 cites W3202593657 @default.
• W4387440328 cites W3203221342 @default.
• W4387440328 cites W4205772148 @default.
• W4387440328 cites W4206677002 @default.
• W4387440328 cites W4210810011 @default.
• W4387440328 cites W4224266833 @default.
• W4387440328 cites W4224304259 @default.
• W4387440328 cites W4225113011 @default.
• W4387440328 cites W4225163272 @default.
• W4387440328 cites W4225625450 @default.
• W4387440328 cites W4225999489 @default.
• W4387440328 cites W4229003058 @default.
• W4387440328 cites W4229924182 @default.
• W4387440328 cites W4281297972 @default.
• W4387440328 cites W4283257632 @default.
• W4387440328 cites W4283743214 @default.
• W4387440328 cites W4285091397 @default.
• W4387440328 cites W4288039038 @default.
• W4387440328 cites W4288039624 @default.
• W4387440328 cites W4289261402 @default.
• W4387440328 cites W4289950985 @default.
• W4387440328 cites W4292451660 @default.
• W4387440328 cites W4294647210 @default.
• W4387440328 cites W4295419374 @default.
• W4387440328 cites W4296462913 @default.
• W4387440328 cites W4296625805 @default.
• W4387440328 cites W4300960788 @default.
• W4387440328 cites W4303453964 @default.
• W4387440328 cites W4306780298 @default.
• W4387440328 cites W4307904635 @default.
• W4387440328 cites W4308597341 @default.
• W4387440328 cites W4311509196 @default.
• W4387440328 cites W4311684916 @default.
• W4387440328 cites W4312221787 @default.
• W4387440328 cites W4315648389 @default.
• W4387440328 cites W4317434821 @default.
• W4387440328 cites W4318482194 @default.
• W4387440328 cites W4328048553 @default.
• W4387440328 cites W4376155645 @default.
• W4387440328 cites W4378983161 @default.
• W4387440328 doi "https://doi.org/10.1080/14787210.2023.2267765" @default.
• W4387440328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37811630" @default.
• W4387440328 hasPublicationYear "2023" @default.
• W4387440328 type Work @default.
• W4387440328 citedByCount "0" @default.

• next